Clinical Trial Update: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining tumor subtypes in non-metastatic pancreatic cancer patients treated with FOLFIRINOX; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas | Phase 2 | Status: RECRUITING